MicroRNAs are endogenous noncoding RNAs that play important roles in a wide variety of biological processes such as apoptosis, development, aging and tumorigenesis. The BCL6 (B-cell lymphoma 6) transcriptional repressor has emerged as a critical therapeutic target in diffuse large B-cell lymphomas (DLBCL), but the mechanisms regulating BCL6 are still unclear. In the current study we screened the microRNA expression profiles in DLBCL specimens and cell lines by qRT-PCR, and found that the expression of miR-144 was significantly downregulated in DLBCL tissues and cell lines and negatively correlated with BCL6 expression. We further demonstrated that BCL6 was the direct target gene of miR-144, and miR-144 suppressed the expression of BCL6 via binding the 3'UTR of BCL6 mRNA.
Introduction
As the most common subtype of non-Hodgkin's lymphoma in adults, diffuse large B cell lymphoma (DLBCL) accounts for approximately 40% of diagnoses that come from the transformation of indolent follicular lymphoma (FL) (1) . The technology of gene expression profiling has been used to stratify DLBCL into biologically meaningful and prognostically relevant subgroups (2) . Although a portion of DLBCL patients can be cured, about 40% die of the disease (3), indicating the urgent need to develop more efficacious therapies.
As an evolutionarily conserved zinc finger transcription factor, B-cell lymphoma 6 (BCL6) protein is highly expressed in various human cancers, including malignancies in the lymphoid system (4). BCL6 protein is an important regulator of B lymphocyte growth and development (5, 6) , and aberrant BCL6 protein expression is involved in the pathogenesis of many kinds of human hematologic malignancies, especially DLBCL (7) (8) (9) . The checkpoint suppression properties of BCL6 are inherently pro-oncogenic and, accordingly, BCL6 is almost universally expressed in DLBCLs.
In DLBCL, high expression of BCL6 is maintained, but the detailed molecular biological function is poorly understood.
MicroRNAs (miRNAs) are noncoding RNAs from 18-24 nucleotides in length that regulate gene expression in many biological processes, including development, proliferation, and differentiation (10) . Recently, miRNAs have attracted attention because of their crucial roles in human diseases and as potential therapeutic targets. miRNAs participate in multiple physiological and pathophysiological processes of B cells, such as B-cell maturation and migration, interaction with immune niche cells, and the generation, production, and class-switching of immunoglobulins (11) . An increasing body of evidence has demonstrated that miRNAs and BCL6 can target one another and mutually adjust their expression which are of great importance in the pathogenesis of various cancers, including breast cancer, prostate cancer, glioblastoma, and myeloma (12) . A study reported that miR-127, as a regulator of (13) . However, little is known about the functions of the miRNAs that associate with BCL6 in DLBCL. Understanding these processes will provide new insights into treatment strategies for DLBCL patients.
MiR-144 was originally identified as an erythroid-specific miRNA required for the survival and maturation of erythroid lineage (14, 15) . Ample studies have also revealed important roles for miR-144 in tumorigenesis and cancer treatment (16) . In different types of cancers, down-regulation of miR-144 has been observed, such as osteosarcoma and mesothelioma, indicating miR-144 as a potential tumor suppressor (17, 18) . Studies have revealed that miR-144 exerts its biological functions by targeting the 3'UTR region of the mRNAs of a number of oncogenes, such as ROCK1 (19) , ZEB1 and ZEB2 (20) , ADAM (21), TIGAR (22), and c-MET (23). However, whether miR-144 regulates BCL6 in carcinogenesis has not been investigated. In DLBCL cell lines, expression of miR-144 was rarely observed, which suggested that the interaction between miR-144 and BCL6 should be explored.
Methods and materials

Samples and Cells
All the non-Hodgkin's lymphoma (NHL) and DLBCL patients' sample were from 
Plasmid constructions and Lentivirus packaging
Luc-BCL6 3'UTR (wild type) were commercially constructed by RiboBio (Guangzhou RiboBio, Guangdong, China), and the mutation of the miR-144-binding sites on Luc-BCL6 3'UTR was performed by TransGen (Beijing TransGen Biotech, Beijing, China). The lentivirus was purchased from GeneChem (GeneChem, China).
Lentivirus carrying BCL6 or vector was packaged following the manufacturer's manual with a ratio of DNA to Lipo of 1:2. Lentivirus were packaged in HEK-293T cells and collected from the medium supernatant. Stable cell lines were established through infecting lentivirus into OCI-Ly3 cells and selected by 300 ng/ml puromycin for 3 weeks.
Oligonucleotide transfection
Scrambled and miR-144 mimics were obtained from RiboBio (Guangzhou RiboBio, The data presented for the qPCR are normalized cycle threshold (ΔCt) values. The formula ΔCt = Ct BCL6 -Ct GAPDH was used, in which a higher ΔCt value means less expression when the formula 2 -ΔΔCt is used.
Western blot
Cell lysates were prepared using 1× lysis buffer (Cell Signal, CA, USA); the same amounts of the cell lysate was subjected to 12% SDS PAGE; after electrophoresis, proteins were transferred onto a nitrocellulose membranes. The primary antibodies to BCL6 (sc-365618) and GAPDH (sc-365062) were purchased from Santa Cruz (Santa Cruz, CA, USA), and diluted at 1:500 for western blot; the second antibody was from Dual-Luciferase Reporter Assay System (Promega, WI, USA), and the values were normalized to Renilla luciferase values. The relative luciferase activity of the mimics group was normalized to that of the scramble groups, and represent data were from at least three independent experiments.
Cell cycle and cell viability assay
Cell cycle assay was analyzed using flow cytometry. Briefly, single cell suspension was fixed with 70% ethanol for 30 min at 4°C. RNA was degraded using RNase and DNA was labeled with propidium iodide (Sigma-Aldrich, MO, USA). Subsequently, 
Cell invasion assay
Invasion was assayed using 24-well BD Matrigel invasion chambers (BD Biosciences, Cowley, UK) in accordance with the manufacturer's instructions. 5 × 10 4 cells per well were seeded in the upper well with DMEM without serum, the lower chamber well was DMEM medium containing 10% FBS. After 24 h incubation, non-invading cells on the top well were removed, and the bottom cells were fixed with 3%
paraformaldehyde, subsequently stained with 0.1% crystal violet, and they were finally extracted with 33% acetic acid and detected quantitatively using a standard microplate reader (at 570 nm). Biotechnologies, CA, USA) was used at a dilution of 1:100 according to immunohistochemistry procedure. Samples were stained with Haematoxylin (Sigma Aldrich, MO, USA) before mounting. Pictures were captured using an OLYMPUS BX51 digital microscope (Olympus, Japan).
Immunohistochemistry
Animal experiments
The animal experiments were performed according to the recommendations in the 
Statistical analysis
Data are expressed as mean ± standard deviation (S.D.). Statistically significant differences were determined using one-way analysis of variance, SPSS version 21 software (IBM). Differences were considered to be statistically significant at P < 0.05. showed that the ΔCt value (ΔCt = Ct BCL6 -Ct GAPDH ) in the DLBCL group, which reflects the relative expression of BCL6, was significantly higher than that in other groups (Fig. 1A) . Western blot assay in some representative samples of these subtypes also confirmed abundant BCL6 protein in the DLBCL patient's sample, as well as in the OCI-Ly3 and SUDHL2 DLBCL cells; however, protein concentrations of BCL6 in follicular lymphoma, Burkett lymphoma and T-cell leukemia were relatively low compared with that in the DLBCL patients, and the same was found in the Raji cells and Jurkat non-Hodgkin's lymphoma cells (Fig. 1B) . The amounts of BCL6 mRNA in the four cell lines were also consistent with protein amounts (Fig.   1C ).
Results
Expression of BCL6 in NHL
Analysis and verification of miRNA target sites
To identify which miRNAs target the BCL6 gene, we first searched the miRNA prediction databases, TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA), and found miR-144, -9, -93, -187, -124, and -10 were predicted as potential miRNAs that bind to BCL6 gene mRNA. To determine functions of these miRNAs in the lymphoma, we examined the expression patents of these miRNAs using qRT-PCR in different subtypes of B-cell lymphoma patients as well as cell lines, and found that expression of miR-144 presented significantly different expression pattern, but other microRNAs had no statistical difference (data not shown). To elucidate the detailed mechanisms of miR-144 in regulating BCL6 expression, we checked the potential targets using TargetScan and found a miR-144 conserved binding site including seven base pairs in the 3'UTR of BCL6 gene mRNA ( Fig. 2A) . We overexpressed the miR-144 in OCI-Ly3 cells by transfecting the miR-144 mimics (Fig. 2B) , and Western blot analysis showed that overexpression of miR-144 attenuated BCL6 expression in OCI-Ly3 cells compared with the scrambled control (Fig. 2C) . A Luc-BCL6-3'UTR luciferase reporter was constructed to determine whether miR-144 directly target the 3'UTR of BCL6 gene mRNA and interrupts transcriptional activity. This reporter was cotransfected with miR-144 mimics (Mimics), for overexpression of miR-144, or the scrambled (Scr) control. 
Luciferase assay results indicated that miR-144 overexpression significantly reduced luciferase activity in the wild-type Luc-BCL6-3'UTR reporter, but when the binding sites were mutated no significant differences were induced in the same cell line, suggesting BCL6 is a direct target of miR-144 (Fig. 2D) .
Negative correlation of miR-144 and BCL6 expression
To explore whether expression of miR-144 and BCL6 correlated in DLBCL patients, BCL6 expression profiles were acquired by immunohistochemistry and western blot, and miR-144 expression was detected with qRT-PCR. All specimens were subjected to immunohistochemical staining for analysis of BCL6 expression. In the DLBCL lymphoma patients, the percentage of samples positive for BCL6 was over 70%, whereas the positive rate was only 14.2% for follicular lymphoma and 12.5% for Burkitt lymphoma. The T-cell lymphomas had a positive rate of 21%, as shown in a representative sample of BLBCL and other lymphoma in Fig. 3 A (complete analytical data in Table 1 ). Some patients' samples were tested for miR-144 expression by qRT-PCR and the result showed that miR-144 maintained low expression in DLBCL patients compared with other subtypes of B-cell lymphoma patients (Fig. 3B) . In contrast, BCL6 expression was abundant in DLBCL patients, but very low in follicular lymphoma, Burkitt lymphoma, and T-cell lymphoma patients (Fig. 3C) . These results indicated that miR-144 and BCL6 expression were negatively correlated in DLBCL patients.
Effects of miR-144 on OCI-Ly3 cells proliferation and invasion
To study the biological functions of miR-144 in DLBCL cells, we used OCI-Ly3 cells to examine the effect of miR-144 on cell proliferation and invasion. We performed CCK-8 assay and flow cytometry to verify the proliferation rate and cell cycle. 48 hours after transfection, the OCI-Ly3 cells transfected with miR-144 mimics proliferated much less than cells transfected with the scrambled and media controls (P < 0.05) (Fig. 4A) . At the same time, the percentage of cells in the G0/G1 phase decreased from 53% to 71% with miR-144 overexpression (Fig. 4B) expression of miR-144 was low in DLBCL cells, which might be related to OCI-Ly3 cell invasion. To study whether miR-144 indeed participates in DLBCL cell invasion, we also performed transwell assays to compare invasion ability at different miR-144 expression levels. We found that miR-144 overexpression in OCI-Ly3 cells resulted in suppressed invasion compared with scrambled and media controls (Fig. 4C) . These data illustrated that miR-144 indeed has important biological roles in DLBCL cells.
Exogenous BCL6 lacking a miR-144 binding site
In order to determine whether miR-144 indeed inhibits proliferation and invasion through its target BCL6, we constructed a BCL6-expressing plasmid with its miR-144 binding sites mutated. When miR-144 mimics and BCL6 overexpression plasmids were cotransfected to OCI-Ly3 cells, miR-144 did not decrease the amount of protein exogenous BCL6 because BCL6 overexpression plasmid lacked miR-144 binding sites (Fig. 5A) . CCK-8 assay and flow cytometry were employed, and although miR-144 was abundant in these cells, BCL6 overexpression still promoted cell growth and accelerated the cell cycle by augmented the percentage of cells in S phage (Fig.   5B, 5C ). In the transwell assay, BCL6 overexpression enhanced cell invasion even though miR-144 was highly expressed (Fig. 5D) . Without the interaction between miR-144 and BCL6 3'UTR, the effect of miR-144 was diminished, suggesting that miR-144 mediates proliferation and invasion through its transcriptional modulation on
BCL6.
Effects of miR-144 on lymphoma development in vivo
To further confirm whether miR-144 could inhibit tumorigenesis in vivo, we used the SCID mice xenograft model to study the impact of miR-144 on DLBCL tumorigenesis and development. A lentivirus carrying miR-144 or Scramble was constructed and used to infect OCI-Ly3 cells, and these cells were selected in puromycin at 300 ng/ml for 3 weeks. We found that the initiation and the growth of tumor were significantly slower in the miR-144 overexpressing cells than the scramble control cells (Fig. 6A) . After the last measurement mice were sacrificed and (Fig. 6B) . We further compared the expression of miR-144 and BCL6 in the tumor tissues isolated from the mice. The protein level of BCL and the RNA level of miR-144 in the tumors were negatively correlated (Fig.   6C, 6D) . Therefore, our animal experiments confirm that miR-144 inhibits DLBCL growth in vivo.
Discussion
As a powerful inhibitor of senescence in primary mouse embryonic fibroblasts, BCL6 expression greatly extends the replicative lifespan of primary human B cells (24).
Recently, BCL6 protein was also shown to be highly expressed in various human cancers including malignancies in the lymphoid system. For example, Chamdin et al reported that the expression of BCL6 in neuroblastoma is significantly associated with poor survival of the patients (25). In addition, BCL6 protein is expressed in the mammary epithelium in non-pregnant and early pregnancy animals (26), and in murine mammary epithelium, BCL6 overexpression prevents duct formation and apoptosis (27). However, BCL6 protein is highly expressed in breast cancer tissues, especially in high-grade ductal breast cancer (26, 27). Overall, the role of BCL6 protein in human cancers other than in the lymphoid system remains to be determined. 
Conclusion
No prior report showed the direct involvement of miR-144 and BCL6 in DLBCL tumorigenesis, which warrants further investigation of this mechanism into DLBCL behavior. Although we should not rule out the involvement of other miRNAs whose target is BCL6, our results provide a proof of principle that miRNAs may be useful for future development of novel therapeutic strategies for DLBCL. Nonetheless, further investigations using animal models as well as more human samples must be done to validate our findings and to further elucidate the detailed mechanisms of miRNA functions in the treatment for lymphoma. 
